Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $300000.0.

  • Maxcyte's Capital Expenditures fell 2610.84% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 3038.45%. This contributed to the annual value of $1.7 million for FY2024, which is 5537.84% down from last year.
  • Per Maxcyte's latest filing, its Capital Expenditures stood at $300000.0 for Q3 2025, which was down 2610.84% from $584000.0 recorded in Q2 2025.
  • Over the past 5 years, Maxcyte's Capital Expenditures peaked at $6.8 million during Q2 2022, and registered a low of $147000.0 during Q4 2024.
  • For the 5-year period, Maxcyte's Capital Expenditures averaged around $1.5 million, with its median value being $804000.0 (2024).
  • As far as peak fluctuations go, Maxcyte's Capital Expenditures skyrocketed by 184473.26% in 2022, and later plummeted by 9254.99% in 2023.
  • Over the past 5 years, Maxcyte's Capital Expenditures (Quarter) stood at $1.1 million in 2021, then soared by 95.55% to $2.2 million in 2022, then plummeted by 58.3% to $915000.0 in 2023, then plummeted by 83.93% to $147000.0 in 2024, then skyrocketed by 104.08% to $300000.0 in 2025.
  • Its Capital Expenditures was $300000.0 in Q3 2025, compared to $584000.0 in Q2 2025 and $653000.0 in Q1 2025.